RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GW Pharmaceuticals - Stock

GW Pharmaceuticals Net Income 2024

GW Pharmaceuticals Net Income

30.28 B USD

Ticker

GWPH

ISIN

US36197T1034

WKN

A1T980

In 2024, GW Pharmaceuticals's profit amounted to 30.28 B USD, a 627.27% increase from the 4.16 B USD profit recorded in the previous year.

The GW Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2025e222.56
2024e30.28
2023e4.16
2022e1.89
2021e-
2020-0.06
2019-0.01
2018-0.34
2017-0.18
2016-0.09
2015-0.06
2014-0.02

GW Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into GW Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by GW Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects GW Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of GW Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into GW Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing GW Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on GW Pharmaceuticals’s growth potential.

GW Pharmaceuticals Revenue, Profit, and EBIT History

DateGW Pharmaceuticals RevenueGW Pharmaceuticals EBITGW Pharmaceuticals Net Income
2025e1.67 B undefined0 undefined222.56 B undefined
2024e1.37 B undefined0 undefined30.28 B undefined
2023e1.14 B undefined0 undefined4.16 B undefined
2022e939.91 M undefined0 undefined1.89 B undefined
2021e749.43 M undefined0 undefined0 undefined
2020527.21 M undefined-51.77 M undefined-58.13 M undefined
2019311.33 M undefined-118.43 M undefined-9.02 M undefined
201819.39 M undefined-343.27 M undefined-341.44 M undefined
201711.46 M undefined-206.17 M undefined-183.16 M undefined
201614.35 M undefined-156 M undefined-88.54 M undefined
201538.38 M undefined-85.31 M undefined-59.93 M undefined
201438.97 M undefined-29.6 M undefined-19.01 M undefined

GW Pharmaceuticals stock margins

The GW Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GW Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GW Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the GW Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the GW Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the GW Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the GW Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the GW Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the GW Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the GW Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

GW Pharmaceuticals Margin History

GW Pharmaceuticals Gross marginGW Pharmaceuticals Profit marginGW Pharmaceuticals EBIT marginGW Pharmaceuticals Profit margin
2025e92.88 %0 %13,290.3 %
2024e92.88 %0 %2,215.37 %
2023e92.88 %0 %363.79 %
2022e92.88 %0 %201.35 %
2021e92.88 %0 %0 %
202092.88 %-9.82 %-11.03 %
201991.26 %-38.04 %-2.9 %
201859.2 %-1,770.23 %-1,760.81 %
201757.02 %-1,799.36 %-1,598.54 %
201673.64 %-1,087.33 %-617.13 %
201590.83 %-222.26 %-156.14 %
201493.14 %-75.98 %-48.79 %

GW Pharmaceuticals Aktienanalyse

What does GW Pharmaceuticals do?

GW Pharmaceuticals PLC is a British company that has been involved in the development and manufacturing of prescription medications based on cannabis since 1998. The company is a global leader in the research of medical cannabis and is headquartered in Cambridge. The history of GW Pharmaceuticals traces back to the founding of the company by Dr. Geoffrey Guy, who focused on the medical use of cannabis. In its early years, the company focused on developing medicinal cannabis strains with high levels of cannabinoids, such as THC or CBD. A pivotal moment for the company was the approval of Sativex in 2010, a medication for the treatment of spastic symptoms in multiple sclerosis. This was the first cannabis-based medication to be approved by a regulatory authority. Since then, GW Pharmaceuticals has expanded its portfolio of products and is involved in various areas, including the treatment of epilepsy, autism, pain, insomnia, and cancer. The company has several medications in late-stage clinical development and plans to bring more medications to the market. GW Pharmaceuticals' business model is based on researching, manufacturing, and selling medical cannabis. The company is an innovative pioneer in this field and works closely with health authorities and medical professionals to ensure the safety and efficacy of its products. GW Pharmaceuticals operates in several sectors, including the development of medical cannabis, the manufacturing of medications, and collaboration with health authorities and medical professionals. The company strives to develop high-quality and safe products that improve patients' quality of life. One of GW Pharmaceuticals' key products is Epidiolex, a medication for the treatment of severe forms of epilepsy in children. The medication contains CBD, one of the compounds found in medical cannabis, and has been approved by the U.S. Food and Drug Administration (FDA). Another important product of GW Pharmaceuticals is Sativex, a spray for the treatment of spastic symptoms in multiple sclerosis. The medication contains a combination of THC and CBD and is approved in several countries. GW Pharmaceuticals also has products in the pipeline targeting the treatment of autism, pain, insomnia, and cancer. The company is committed to advancing the use of medical cannabis and its compounds in medical practice and contributing to the improvement of health. Overall, GW Pharmaceuticals has made a significant contribution to the research and development of medical cannabis and has established itself as a leader in this field. The company is dedicated to developing high-quality medications that improve patients' lives and contribute to improving health. GW Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding GW Pharmaceuticals's Profit Margins

The profit margins of GW Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of GW Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating GW Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

GW Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When GW Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about GW Pharmaceuticals Stock

How much profit has GW Pharmaceuticals made this year?

GW Pharmaceuticals has made 30.28 B USD this year.

How has the profit developed compared to last year?

The profit has increased by 627.27% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does GW Pharmaceuticals publish its earnings?

GW Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of GW Pharmaceuticals?

The profits of GW Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of GW Pharmaceuticals?

You can learn more about the earnings of GW Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does GW Pharmaceuticals pay?

Over the past 12 months, GW Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, GW Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of GW Pharmaceuticals?

The current dividend yield of GW Pharmaceuticals is .

When does GW Pharmaceuticals pay dividends?

GW Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of GW Pharmaceuticals?

GW Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of GW Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is GW Pharmaceuticals located?

GW Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von GW Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GW Pharmaceuticals from 6/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/18/2024.

When did GW Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/18/2024.

What was the dividend of GW Pharmaceuticals in the year 2023?

In the year 2023, GW Pharmaceuticals distributed 0 USD as dividends.

In which currency does GW Pharmaceuticals pay out the dividend?

The dividends of GW Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The GW Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von GW Pharmaceuticals

Our stock analysis for GW Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GW Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.